Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation

被引:20
作者
Forslow, Ulrica
Mattsson, Jonas
Ringden, Olle
Klominek, Julius
Remberger, Mats
机构
[1] Karolinska Univ Hosp, Div Resp Med &Allergol, SE-14186 Stockholm, Sweden
[2] Karolinska Inst, Karolinska Univ Hosp, Dept Med, Div Resp Med & Allergol, SE-14186 Stockholm, Sweden
[3] Karolinska Inst, Karolinska Univ Hosp, CAST, Ctr Allogen Stem Cell Transplantat, SE-14186 Stockholm, Sweden
[4] Karolinska Inst, Karolinska Univ Hosp, Dept Clin Immunol, Stockholm, Sweden
关键词
D O I
10.1080/00365540600786481
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pulmonary complications after allogeneic hematopoietic stem-cell transplantation (HSCT) remain 1 of the most important causes of morbidity and mortality. This study evaluates the change over time of incidence, aetiology and risk factors for death related to pneumonia within 3 months after HSCT. 997 patients who underwent HSCT were studied retrospectively. Most patients (83%) had a haematological malignancy. The majority (89%) had an HLA-A, -B, and -DR matched related or unrelated donor. Conditioning consisted of cyclophosphamide and total-body irradiation or busulfan and graft-versus-host disease prophylaxis of cyclosporin and methotrexate in most cases. Death related to pneumonia occurred in 56 (5.6%) patients. Cytomegalovirus (37%) was the main pathogen involved, especially during the first 2 decades studied. In the multivariate risk factor analysis, we found that death from pneumonia was significantly associated with receiving a T-cell depleted graft (p < 0.001), bacteraemia (p=0.001), and y of transplantation (p < 0.001). In patients receiving a transplant during the last decade, the incidence of death related to pneumonia was 2.8% compared to 8.9% during the first decade. We conclude that the rate of mortality related to pneumonia has decreased over time, possibly as a result of improved diagnostic, prophylactic and therapeutic methods and treatment.
引用
收藏
页码:970 / 976
页数:7
相关论文
共 25 条
[1]   Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation [J].
Broers, AEC ;
van der Holt, R ;
van Esser, JWJ ;
Gratama, JW ;
Henzen-Logmans, S ;
Kuenen-Boumeester, V ;
Löwenberg, B ;
Cornelissen, JJ .
BLOOD, 2000, 95 (07) :2240-2245
[2]   Cytomegalovirus infection after bone marrow transplantation in children [J].
Castagnola, E ;
Cappelli, B ;
Erba, D ;
Rabagliati, A ;
Lanino, E ;
Dini, G .
HUMAN IMMUNOLOGY, 2004, 65 (05) :416-422
[3]   Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation [J].
Chen, CS ;
Boeckh, M ;
Seidel, K ;
Clark, JG ;
Kansu, E ;
Madtes, DK ;
Wagner, JL ;
Witherspoon, RP ;
Anasetti, C ;
Appelbaum, FR ;
Bensinger, WI ;
Deeg, HJ ;
Martin, PJ ;
Sanders, JE ;
Storb, R ;
Storek, J ;
Wade, J ;
Siadak, M ;
Flowers, MED ;
Sullivan, KM .
BONE MARROW TRANSPLANTATION, 2003, 32 (05) :515-522
[4]   Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation [J].
Della Volpe, A ;
Ferreri, AJM ;
Annaloro, C ;
Mangili, P ;
Rosso, A ;
Calandrino, R ;
Villa, E ;
Lambertenghi-Deliliers, G ;
Fiorino, C .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (02) :483-488
[5]   Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant:: A multicenter project [J].
Dettenkofer, M ;
Wenzler-Röttele, S ;
Babikir, R ;
Bertz, H ;
Ebner, W ;
Meyer, E ;
Rüden, H ;
Gastmeier, P ;
Daschner, FD .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (07) :926-931
[6]  
EINSELE H, 1995, BLOOD, V86, P2815
[7]  
GROB J, 1986, BONE MARROW TRANS S1, V49
[8]   Reduced intensity conditioning regimens -: Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma [J].
Hentschke, P ;
Barkholt, L ;
Uzunel, M ;
Mattsson, J ;
Wersäll, P ;
Pisa, P ;
Martola, J ;
Albiin, N ;
Wernerson, A ;
Söderberg, M ;
Remberger, M ;
Thörne, A ;
Ringdén, O .
BONE MARROW TRANSPLANTATION, 2003, 31 (04) :253-261
[9]   Results of different strategies for reducing:: Cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients [J].
Ljungman, P ;
Aschan, J ;
Lewensohn-Fuchs, I ;
Carlens, S ;
Larsson, K ;
Lönnqvist, B ;
Mattsson, J ;
Sparrelid, E ;
Winiarski, J ;
Ringdén, O .
TRANSPLANTATION, 1998, 66 (10) :1330-1334
[10]  
Ljungman P, 1996, BONE MARROW TRANSPL, V17, P583